

**Virginia Medicaid Preferred Drug List
Annual Review Process
Phase I**

REVISED SCHEDULE

The Virginia Medicaid Pharmacy and Therapeutics Committee (P&T) will be conducting the annual review of drug classes for Phase I of the Preferred Drug List (PDL) program. The Virginia Medicaid program will continue utilizing Virginia specific contracts for pricing and supplemental rebates directly with manufacturers. Manufacturers are encouraged to provide supplemental rebate offers for consideration by the Commonwealth of Virginia.

The Department of Medical Assistance Services (DMAS) has set the anticipated schedule for the review of drug classes implemented in January 2004 (Phase I). This includes the first 13 drugs classes that were reviewed in the fall of 2003 and whose contracts end December 31, 2004. The following therapeutic classes of drugs will be reviewed for continued PDL inclusion:

Proton Pump Inhibitors
Nasal Steroids
Non-Sedating Antihistamines and combination products
Histamine-2 Receptor Antagonists
Inhaled Beta Adrenergics
COX-2 Inhibitors
Inhaled Steroids
HMG-CoA Reductase Inhibitors (statins)
Sedative Hypnotics
Angiotensin Converting Enzyme Inhibitors and combination products
Angiotensin Receptor Antagonists and combination products
Beta-blockers
Dihydropyridine Calcium Channel Blockers
Non-Dihydropyridine Calcium Channel Blockers

- Friday, June 25, 2004: A comprehensive bidding package with instructions will be sent electronically to manufacturers by First Health Services Corporation.
- Friday, August 6, 2004: Manufacturers' final supplemental rebate offers must be submitted to First Health Services by close of business. The Department expects to receive best and final offers by this date.
- Monday, September 20, 2004: Meeting of the P&T Committee to review clinical information, pricing information, and to select which drugs will not require prior authorization.
- Friday, October 15, 2004: First Health Services must receive all manufacturer-executed supplemental rebate contracts by close of business. Should the final contract not be received at this time, previous offers will be considered rescinded.
- Monday, November 1, 2004: Final PDL posted on the DMAS website.
- Monday, January 3, 2005: Implement prior authorization requirement for drugs that were not selected to be on the PDL.

If you have any questions, regarding the PDL process, please contact pdlinput@dmass.virginia.gov

All correspondence and inquiries regarding the annual review process should be directed to:

First Health Services Corporation

Attention: David Adams, Clinical Management Consultant

Rebate Contracting and Pricing

4300 Cox Road

Glen Allen, Virginia 23060

Phone: 804-965-7689

Email: adamsda@fhsc.com